PIK3CB and diffuse large B-cell lymphoma: More importantly, we noticed that AZD2014 treatment was able to sensitize previously AZD8186-resistant DLBCL cells to PI3Kβ/δ inhibition, confirming the importance of PI3K/AKT/mTOR reactivation as a resistance mechanism in DLBCL (Fig. 5c; Supplementary Fig. 9).